Skip Navigation LinksHome > February 2014 - Volume 26 - Issue 1 > The renaissance of endocrine therapy in breast cancer
Text sizing:
A
A
A
Current Opinion in Obstetrics & Gynecology:
doi: 10.1097/GCO.0000000000000039
BREAST CANCER: Edited by Gottfried E. Konecny

The renaissance of endocrine therapy in breast cancer

Williams, Nicolea; Harris, Lyndsay N.a,b

Collapse Box

Abstract

Purpose of review

Endocrine therapy for breast cancer has been the cornerstone of treatment for over a century since the discovery of the regressive effect of oophorectomy on ‘cancer of the mamma’ in 1896 by Beatson. Studies in the prevention and treatment of both early and metastatic breast cancer will be reviewed with a focus on recent large randomized clinical trials that may be practice changing.

Recent findings

Data from pivotal clinical trials that looked at the duration of adjuvant tamoxifen therapy in premenopausal women will be discussed. In addition, several recent clinical trials that address the optimal sequence of endocrine therapy and advances in the treatment of endocrine-resistant metastatic disease will be reviewed. New findings from molecular studies that demonstrate targets in the endocrine axis and the role of aromatase inhibitors in the prevention setting will be highlighted.

Summary

Overall, these clinical trials show the benefit of aromatase inhibitors in the prevention setting, longer duration of tamoxifen in the adjuvant setting for premenopausal women, and new biologic agents with hormonal therapies.

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.